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ABSTRACT OF THESIS 
 
 
 
 
REINFORCING, SUBJECTIVE, AND COGNITIVE EFFECTS OF 
METHAMPHETAMINE DURING D-AMPHETAMINE MAINTENANCE 
 
Translational research suggests that agonist replacement may be a viable 
treatment approach for managing methamphetamine dependence. This study 
sought to determine the effects of d-amphetamine maintenance on 
methamphetamine self-administration in stimulant using participants. A cognitive 
battery was used to determine the performance effects of methamphetamine 
alone and during d-amphetamine maintenance. During each maintenance 
condition, participants first sampled a dose of intranasal methamphetamine then 
had the opportunity to respond on a progressive ratio task to earn portions of the 
sampled dose. Subject-rated drug-effect and physiological measures were 
completed prior to and after sampling methamphetamine. Methamphetamine was 
self-administered as function of dose regardless of the maintenance condition. 
Methamphetamine produced prototypical subject-rated effects, some of which 
were attenuated by d-amphetamine maintenance. Methamphetamine was well 
tolerated during d-amphetamine maintenance and no adverse events occurred. 
The self-administration results are concordant with those of clinical trials that 
show d-amphetamine did not reduce methamphetamine use. Generally, there 
was no difference in cognitive performance after methamphetamine 
administration during both placebo and d-amphetamine maintenance. Overall d-
amphetamine does not appear to be a viable treatment for preventing 
methamphetamine relapse, but translational literature suggests that other agonist 
medications or the combination of pharmacotherapy and behavioral therapies 
may be effective. 
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drug-effects, cognitive performance  
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Chapter One. Significance and Background 
Methamphetamine use disorders are a significant problem in the United 
States. In 2011, 439,000 individuals over 12 years of age reported using 
methamphetamine. The number of new users of methamphetamine 12 years of 
age and older increased between 2010 and 2011 (Substance Abuse and Mental 
Health Services Administration (SAMHSA), 2011; SAMHSA, 2012). Not only are 
the number of individuals using methamphetamine increasing, but the cost to 
society, including premature death, health care costs, and costs of incarceration, 
is staggering. Using the most recently available data, the estimated total cost of 
methamphetamine abuse in the United States was over $23 billion in 2005 
(Nicosia, Pacula, Kilmer, Lundberg, & Chiesa, 2009). The increasing number of 
individuals using methamphetamine and the high cost to society contribute to the 
importance of identifying an effective treatment for methamphetamine abuse, as 
no universally effective treatments are currently available. 
Below I review the available therapeutic approaches for methamphetamine 
dependence that have been empirically tested.  
Behavioral Therapy 
Behavioral therapies that have been tested for treatment of 
methamphetamine abuse include motivational interviewing, cognitive behavioral 
therapy, relapse prevention, the Matrix Model, and contingency management. 
Motivational interviewing is a type of therapy designed to help increase an 
individual’s motivation to change their substance use patterns (Baker, Boggs, & 
Lewin, 2001; Baker, et al., 2002; Baker, et al., 2005). Cognitive behavioral 
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therapy is related to basic principles of conditioning and learning and involves 
teaching individuals skills to stop or reduce their substance use (Lee & Rawson, 
2008; Vocci & Montoya, 2009). Cognitive behavioral therapy has been expanded 
into other more specific therapies, such as relapse prevention. Relapse 
prevention aims to help individuals recognize and cope with situations and 
feelings that may contribute to relapse in order to increase periods of abstinence 
(Baker, Boggs, & Lewin, 2001; Baker, et al., 2005; Lee & Rawson, 2008). The 
Matrix Model was designed specifically to address treatment needs of stimulant 
abusers and is an intensive multi-week program that includes many types of 
treatment such as relapse prevention, individual therapy, group sessions, and 
family education. This model also encourages individuals to become involved in 
social support groups, such as Alcoholics Anonymous (Obert, et al., 2000; 
Rawson, et al., 1994, Rawson, et al., 2004; Vocci & Montoya, 2009). 
Contingency management is a treatment model that provides incentives, such as 
vouchers for goods or services or payment, for meeting set behavioral goals 
(e.g., negative urine samples or self-reported abstinence) (for review see: Lee & 
Rawson, 2008; Roll, 2007; and Vocci & Montoya, 2009; Roll, et al., 2006).  
One example of a behavioral intervention that has been tested is contingency 
management, which has shown promise as a potential treatment for 
methamphetamine abuse. Methamphetamine abusing participants receiving 
treatment, including contingency management, were more likely to provide 
amphetamine or methamphetamine negative urine samples, have increased 
retention in treatment, and have longer periods of abstinence (for review see: 
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Lee & Rawson, 2008 and Roll, 2007; Vocci & Montoya, 2009; Rebak, Peck, 
Dierst-Davies, Nuno, Kamien, & Amass, 2010; Roll, et al., 2006). While 
contingency management seems promising, results at follow-up are inconsistent. 
Some studies show maintained abstinence at follow-up, while others show that 
the differences between contingency management and treatment as usual or no 
treatment is not maintained at follow-up (for review see: Lee & Rawson, 2008 
and Roll, 2007; Vocci & Montoya, 2009; Rebak, Peck, Dierst-Davies, Nuno, 
Kamien, & Amass, 2010; Roll, et al., 2006). Recent reviews have shown similar 
results with other cognitive and behavioral therapies (i.e., motivational 
interviewing, cognitive behavioral therapy, and Matrix Model treatment), with 
increased rates of stimulant negative urine samples, increased treatment 
retention, and increased continuous abstinence compared to treatment as usual 
or no treatment. However, beneficial effects of the treatments have not been 
shown to be present at follow-up (Lee & Rawson, 2008; Vocci & Montoya, 2009) 
Overall, behavioral therapies have shown positive results in promoting 
methamphetamine abstinence during treatment, but do not produce lasting 
changes after treatment. This suggests that other strategies, like 
pharmacotherapy, are needed. 
Pharmacotherapy 
Methamphetamine belongs to a class of drugs called phenylethylamines and 
is lipophilic, which allows it to readily cross the blood-brain barrier. 
Methamphetamine increases the release of endogenous monoamines, primarily 
dopamine, through different biological processes. First, methamphetamine is 
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readily transported into the nerve terminal by diffusion across the cell membrane 
and is also transported by catecholamine-uptake transporters. Once in the nerve 
terminal, methamphetamine interacts with vesicular monoamine transporter-2 
(VMAT-2) to redistribute monoamines from vesicles into the cytosol. Also, 
methamphetamine reverses catecholamine-uptake transporters causing 
monoamines that are free in the cytosol to be moved into the synapse. Finally, 
methamphetamine inhibits the activity of monoamine oxidase, which breaks 
down monoamines in the cell, and promotes tyrosine hydroxylase, which allows 
for increased synthesis of dopamine (reviewed in Schep, Slaughter, & Beasley, 
2010). 
Based on this neuropharmacology, the dopamine system has been targeted 
for medications development. Both antagonist treatment and agonist 
replacement have been tested (for reviews see Herin, Rush, & Grabowsi 2010; 
Karila, Weinstein, Aubin, Benyamina, Reynaud, & Batki, 2010; Rush, Vansickel, 
Lile, & Stoops, 2009). Antagonists block the effects of the abused drug to 
extinguish self-administration. Agonist replacement produces cross tolerance to 
the drug of abuse by diminishing the high that is achieved when the drug of 
abuse is taken, which leads to extinction of drug taking (for reviews see Herin, 
Rush, & Grabowsi 2010; Karila, Weinstein, Aubin, Benyamina, Reynaud, & Batki, 
2010; Rush, Vansickel, Lile, & Stoops, 2009). 
The first pharmacologic approach that was tested to treat methamphetamine 
abuse was typical antipsychotics as an antagonist treatment. Dopamine is 
thought to mediate the abuse of methamphetamine and typical antipsychotics are 
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D2 antagonists, which should block methamphetamine from binding to dopamine 
receptors. Pimozide is one example of an atypical antipsychotic that has been 
tested (for review: Brauer, Goudie, & de Wit, 1997). Pimozide has been shown to 
block the discriminative effects of 1 mg/kg amphetamine in amphetamine-trained 
rats (Nielsen & Jepsen, 1985). Also, rats pretreated with pimozide self-
administered fewer doses of amphetamine and were slower to reinstate 
responding after extinction compared to placebo treated animals (Yokel & Wise, 
1976). In a study using dogs, pretreatment with pimozide increased 
amphetamine self-administration, which has been linked to increased responding 
for drug early in extinction models (Risner & Jones, 1976). However, pimozide 
inconsistently blocked amphetamine discrimination in rhesus monkeys, with 
some doses effective in a subset of the sample and other animals in the sample 
displaying no effect of pimozide pretreatment. Additionally, because of a 
decrease in the response rate when pimozide and amphetamine were combined, 
higher doses were not tested (Kamien & Woolverton, 1989). In humans, results 
have also been mixed. One study showed that 2 mg of pimozide blocked 
increases in arousal after a 10 mg dose of d-amphetamine in healthy volunteers 
(Silverstone, Fincham, Wells, & Kyriakides, 1980). However, in another study 
with healthy volunteers, pretreatment with 1 or 2 mg pimozide had no effect on 
10 or 20 mg doses of d-amphetamine (Brauer & de Wit, 1996). In a later study, a 
higher dose of pimozide (8 mg) was tested in healthy volunteers and found that 
pimozide had no effect on subjective effects after 10 or 20 mg of d-amphetamine. 
Additionally, some side effects including sedation, agitation, restlessness, facial 
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spasms, and rigidity were noted (Brauer & de Wit, 1997). Similar research has 
been done with other typical antipsychotics, including haloperidol, 
chlorpromazine, and fluphenizine (for review see Brauer, Goudie, & de Wit, 1997; 
Colpaert, Niemegeers, & Janssen, 1978; Schechter & Cook, 1975; Wilson & 
Schuster, 1972; Arnt, 1996). 
In response to the mixed results and side effects associated with typical 
antipsychotics, atypical antipsychotics have been tested as a possible antagonist 
treatment. Atypical antipsychotics, including risperidone and aripiprazole, were 
considered as possible pharmacotherapies, because of their action on dopamine 
and serotonin receptors. Risperidone is a dopamine and serotonin antagonist, 
and it is believed that blocking monoamine binding through the use of an 
antagonist may decrease the rewarding effects of methamphetamine (Fletcher, 
1998; Grabowski, et al., 2000; Meert, Dr Haes, Vermote, & Janssen, 1990; 
Meredith, et al., 2009; Rush, Stoops, Hays, Glaser, & Hays, 2003; Wachtel, 
Ortengren, & de Wit, 2002).  Preclinical experiments have shown that risperidone 
reduced drug-appropriate responding to d-amphetamine in d-amphetamine 
trained rats (Arnt, 1996; Meert, De Haes, Vermote, & Janssen, 1990) and self-
administration of d-amphetamine in rats (Fletcher, 1998). When tested in healthy 
human volunteers, acute risperidone pretreatment did not significantly reduce 
subject-rated drug-effects of methamphetamine, but did produce a trend toward 
decreased subject-rated drug-effects (Wachtel, Ortengren, & de Wit, 2002). In 
another study, healthy human volunteers trained to discriminate d-amphetamine 
showed that pretreatment with risperidone decreased drug-appropriate 
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responding to d-amphetamine and reduced subject-rated drug-effects of d-
amphetamine. However, this study also showed some performance impairments 
after risperidone pretreatment (Rush, Stoops, Hays, Glaser, & Hays, 2003). In an 
open label clinical trial injectable risperidone was tested for the treatment of 
methamphetamine dependence, only forty-four percent of all possible urine 
samples were negative for methamphetamine, when analyzed using an intent-to-
treat model (Meredith, et al., 2009). Also, patients experienced negative side-
effects of risperidone including sedation, which occurred in eighty percent of 
participants, and akathisia, which occurred approximately seventeen percent of 
participants (Meredith, et al., 2009). A double-blind placebo-controlled trial was 
designed to test varying doses of risperidone for the treatment of cocaine 
dependence. Participants in the 8 mg risperidone condition had a greater 
proportion of cocaine positive urine samples in the first month of the trial 
compared to all of the other groups, including placebo (Grabowski, et al., 2000). 
None of the participants randomized to the highest dose condition, 8 mg 
risperidone, completed the study. Over all of the doses tested, risperidone 
treatment did not improve outcomes or retention. Additionally, participants 
experienced multiple negative side effects of the medication (Grabowski, et al., 
2000). The increase in positive urine screens, poor retention, and multiple 
negative side effects suggest that risperidone is not likely to be an effective 
pharmacotherapy as treatment retention and compliance may be problematic. 
Aripiprazole, another atypical antipsychotic, which is a dopamine and 
serotonin partial agonist, has also been tested as a potential pharmacotherapy 
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for methamphetamine dependence. Similar to risperidone, aripiprazole 
pretreatment showed promising results in healthy human volunteers (Sevak, et 
al., 2011; Stoops, 2006). Clinical trials testing aripiprazole for methamphetamine 
dependence have generally shown no significant reduction in methamphetamine 
use (Coffin, et al., 2012; Tiihonen, et al., 2007). Additionally, one of the trials was 
ended early when interim analysis showed that participants in the aripiprazole 
arm of the study were more likely to submit a urine sample positive for 
amphetamine than participants receiving placebo (Tiihonen, et al., 2007). This 
increase in drug use in the aripiprazole condition is disconcerting and suggests 
that antagonist treatment may not be an effective strategy for treating 
methamphetamine abuse. These studies suggest that a different approach is 
needed to identify a potential pharmacotherapy for treating methamphetamine 
dependence.  
Agonist replacement may be an alternative to antagonist treatment for 
methamphetamine dependence. Dopamine agonists have been proposed as a 
potential pharmacotherapy as they may increase extracellular dopamine, which 
has been found to be depleted after long-term stimulant use, without the 
rewarding properties produced by methamphetamine (reviewed in: Herin, Rush, 
& Grabowski, 2010; Moeller, Schmitz, Herin, & Kjome, 2008). Agonist 
replacement is commonly used for other types of substance use, including 
methadone for opiate abuse and nicotine replacement for tobacco use. In 
addition, dopamine agonists have shown promising results when tested for 
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treating cocaine dependence (reviewed in: Herin, Rush, & Grabowski, 2010; 
Moeller, Schmitz, Herin, & Kjome, 2008). 
Few studies have been conducted to test agonist replacement with 
methamphetamine. However there is an extensive literature related to agonist 
replacement for treating cocaine dependence that may be germane to the 
approach of using agonist replacement for methamphetamine abuse. Numerous 
dopamine agonists have been tested for treating cocaine dependence including 
d-amphetamine, which can provide translational evidence for the use of d-
amphetamine for methamphetamine abuse. Preclinical studies with rats have 
shown that chronic maintenance with d-amphetamine decreases cocaine taking 
on a progressive-ratio schedule of self-administration (Chiodo & Roberts, 2009), 
decreases breakpoints of responding for cocaine (Chiodo, Läck, Roberts, 2008), 
and produces a rightward shift in the discrimination and self-administration 
curves of cocaine (Peltier, Li, Lytle, Taylor, & Emmett-Oglesby, 1996). Similarly, 
preclinical studies using rhesus monkeys have shown that chronic pretreatment 
with d-amphetamine reduced self-administration of cocaine (Czoty, Gould, 
Martelle, & Nader, 2011; Czoty, Martelle, & Nader, 2010; Foltin & Evans, 1998; 
Negus & Mello, 2003a; Negus & Mello, 2003b). Human laboratory studies with 
healthy non-treatment seeking cocaine users have shown that maintenance on 
d-amphetamine reduced some of the positive subjective effects of intranasal 
cocaine and decreased self-administration of 20 mg of cocaine (Rush, Stoops, & 
Hays, 2009; Rush, Stoops, Sevak, & Hays, 2010). Finally, clinical trials have 
shown positive results using d-amphetamine as a potential treatment for cocaine 
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dependence (Grabowski, et al., 2001; Grabowski, et al., 2004; Shearer, Wodak, 
van Beek, Mattick, & Lewis, 2003). Two clinical trials have shown decreases in 
cocaine positive urine samples with an escalating dose of 30 mg to 60 mg d-
amphetamine (Grabowski, et al., 2001; Grabowski, et al., 2004). Another clinical 
trial tested 60 mg d-amphetamine and did not find a significant decrease in 
positive urine samples, but participants in the treatment group reported 
significantly less cocaine use and lower levels of craving compared to those 
receiving placebo treatment (Shearer, Wodak, van Beek, Mattick, & Lewis, 
2003). These findings provide evidence for the use d-amphetamine as a potential 
pharmacotherapy for cocaine dependence, which may also translate to 
methamphetamine dependence. 
Similar to the findings with cocaine, dopamine agonists that have been tested 
for methamphetamine dependence and show promise as a potential 
pharmacotherapy, with fewer unpleasant side effects or performance 
impairments than other classes of medications that have been tested (Herin, 
Rush, & Grabowsi, 2010; Karila, Weinstein, Aubin, Benyamina, Reynaud, & 
Batki, 2010). A recent study tested subject-rated drug-effects of varying doses of 
methamphetamine during d-amphetamine maintenance compared to placebo in 
chronic stimulant abusing individuals. It was found that 45 mg/day d-
amphetamine reduced subject-rated drug-effects of methamphetamine 
significantly compared to placebo (Rush, Stoops, Lile, Glaser, & Hays, 2011). 
This suggests that d-amphetamine may be effective for treating 
methamphetamine abuse, but this study did not test to see if d-amphetamine 
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would reduce self-administration of methamphetamine in a controlled laboratory 
or clinical setting. One clinical trial showed that pretreatment with d-amphetamine 
decreased illicit amphetamine use in intravenous drug users (Moeller, Schmitz, 
Herin, & Kjome, 2008). Another clinical trial was designed to test the efficacy of 
sustained release d-amphetamine for the treatment of methamphetamine abuse 
in treatment seeking methamphetamine users. The data showed that treatment 
with 60 mg of sustained-release d-amphetamine did not reduce 
methamphetamine use compared to placebo maintenance (Galloway, et al., 
2011). Similarly, another clinical trial demonstrated that maintenance on 110 mg 
d-amphetamine for the treatment of methamphetamine did not reduce 
methamphetamine abuse compared to placebo maintenance (Longo, et al., 
2009). The results from clinical trials are mixed, which along with a promising 
signal from the human laboratory, suggests that more research is needed to 
determine if d-amphetamine may be an effective pharmacotherapy for 
methamphetamine abuse.    
Overall, a universally effective pharmacotherapy for methamphetamine abuse 
has not been identified. While there has not been much work done testing 
agonist replacement as a pharmacotherapy for methamphetamine, previous work 
shows a good signal that agonist replacement may be effective and so far 
agonist replacement has shown the best signal as a pharmacotherapy for 
cocaine dependence. These findings suggest that more work is needed to test 
agonist replacement for methamphetamine dependence. 
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Cognitive Impairment as a Target for Medications Development 
A recent target for medication development is the remediation of cognitive 
deficits related to chronic stimulant abuse. This has stemmed from studies that 
have associated poorer treatment outcomes and early treatment drop-out with 
performance on various measures of cognitive functioning (Ahronovich, Hasin, 
Brooks, Liu, Bisaga, & Nunes, 2006; Ahronovich, Nunes, & Hasin, 2003; Brewer, 
Worhunsky, Carroll, Rounsville, & Potenza, 2008; Hester, Lee, Pennay, Nielson, 
& Ferris, 2010; Moeller, Dougherty, Barratt, Schmitz, Swann, & Grabowski, 2001; 
Turner, LaRowe, Horner, Herron, & Malcolm, 2009).  
The cocaine Stroop task assesses for a bias toward drug related stimuli by 
recording the reaction time for participants to respond to the color of both neutral 
and drug related words. The cocaine Stroop has consistently shown that chronic 
stimulant using individuals show an attention bias toward salient (i.e., drug 
related) words (Brewer, Worhunky, Carroll, Rounsaville, & Potenza, 2008; 
Gardini, Caffarra, & Venneri, 2009; Hester, Lee, Pennay, Nielson, & Ferris, 2010; 
Liu, Lane, Schmitz, Waters, Cunningham, & Moeller, 2011; Sharma & Money, 
2010). There is an inverse relationship between performance on the cocaine 
Stroop and treatment retention, such that a higher attention bias is associated 
with less time in treatment (Brewer, Worhunsky, Carroll, Rounsaville, & Potenza, 
2008; Hester, Lee, Pennay, Nielson, & Ferris, 2010).  
Other studies have investigated impulsivity in stimulant users, as individuals 
who are more impulsive may choose short-term reinforcement from using a drug 
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as opposed to longer-term reinforcement associated with abstinence. These 
studies have found that chronic stimulant users tend to be more impulsive 
compared to controls on the Barratt Impulsiveness Scale and tend to choose less 
advantageous decks on the Iowa Gambling Task (Kjome et al., 2010; Moeller, 
Dougherty, Barratt, Schmitz, Swann, & Grabowski, 2001).  
Cognitive performance on a battery of tests has also been assessed as part 
of two clinical trails. These studies showed differences in cognitive performance 
of treatment completers compared to dropouts, with dropouts displaying 
significantly poorer performance on measures of attention, memory, spatial ability 
and processing, and mental reasoning (Ahronovich, Hasin, Brooks, Liu, Bisaga, 
& Nunes, 2006; Ahronovich, Nunes, & Hasin, 2003). 
Further research is needed to assess different domains of cognitive function 
to see if deficits can be identified. Additionally, research has not yet been done to 
determine if cognitive performance of stimulant users can be improved using 
pharmacological methods.   
Summary 
Methamphetamine abuse is a significant problem in the United States, with 
over four hundred thousand people reporting past month use of 
methamphetamine and increasing numbers of people initiating use (SAMHSA, 
2012). Also, methamphetamine abuse is associated with a very high cost to 
society (Nicosia, Pacula, Kilmer, Lundberg, & Chiesa, 2009). Behavioral 
therapies, especially contingency management, have shown some potential as a 
treatment for methamphetamine abuse. However, differences in use observed 
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between treatment groups and either treatment as usual or no treatment do not 
always persist at follow-up (for review see: Lee & Rawson, 2008 and Roll, 2007; 
Vocci & Montoya, 2009; Rebak, Peck, Dierst-Davies, Nuno. Kamien, & Amass, 
2010; Roll, et al., 2006). It is possible that behavioral therapies combined with 
pharmacotherapy could produce more robust patterns of abstinence, but an 
effective pharmacotherapy has yet to be identified. Studies testing d-
amphetamine as a potential pharmacotherapy for methamphetamine abuse have 
shown decreases in illicit stimulant abuse in intravenous amphetamine users and 
decreases in subject-rated drug-effects after methamphetamine administration 
(Moeller, Schmitz, Herin, & Kjome, 2008; Rush, Stoops, Lile, Glaser, & Hays, 
2011, respectively). However, a clinical trial testing d-amphetamine as a 
treatment for methamphetamine abuse in treatment seeking methamphetamine 
users did not show a reduction in methamphetamine use compared to placebo 
(Galloway, et al., 2011). Finally, remediation of cognitive deficits associated with 
chronic stimulant abuse have become a target for medications development, 
since recent studies have shown that poor performance on cognitive measures 
are associated with poor treatment outcomes and retention (Ahronovich, Hasin, 
Brooks, Liu, Bisaga, & Nunes, 2006; Ahronovich, Nunes, & Hasin, 2003; Brewer, 
Worhunsky, Carroll, Rounsville, & Potenza, 2008; Hester, Lee, Pennay, Nielson, 
& Ferris, 2010; Moeller, Dougherty, Barratt, Schmitz, Swann, & Grabowski, 2001; 
Turner, LaRowe, Horner, Herron, & Malcolm, 2009). It is likely that a successful 
methamphetamine intervention will need to encompass each of these 
approaches.  
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Chapter Two. Purpose of Project 
The aim of the present study was to evaluate d-amphetamine as a potential 
pharmacotherapy for methamphetamine abuse. This was accomplished by 
examining the subject-rated drug effects, self-administration, cognitive 
performance, and physiological measures after the administration of varying 
doses of methamphetamine during chronic maintenance on either d-
amphetamine or placebo. These measures have previously been shown to be 
sensitive to the effects of methamphetamine (Lile, Stoops, Glaser, Hays, & Rush, 
2011; Rush, Stoops, Lile, Glaser, & Hays, 2011; Sevak, Stoops, Hays, & Rush, 
2009; Sevak, Vansickel, Stoops, Glaser, Hays, & Rush, 2011). 
Chapter Three. Hypothesis 
Behavioral 
Methamphetamine will be self-administered by participants more than 
placebo. During d-amphetamine maintenance, participants will self-administer 
fewer doses of methamphetamine than during placebo maintenance. 
Methamphetamine administered alone will dose dependently increase positive 
subject-rated drug-effects (e.g., Like Drug; Willing to Take Again). During d-
amphetamine maintenance, participants will report lower levels of drug-effects 
compared to placebo maintenance. 
Cognitive 
d-Amphetamine maintenance. d-Amphetamine alone will improve 
participants’ performance on the cognitive battery compared to placebo 
maintenance.  
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Methamphetamine challenge. Methamphetamine administered alone and in 
combination with d-amphetamine will dose-dependently improve participants’ 
performance on the cognitive battery compared to performance after placebo 
administration. d-Amphetamine maintenance will attenuate impairments 
observed after methamphetamine administration. 
Physiological 
Methamphetamine will dose dependently increase heart rate and blood 
pressure. d-Amphetamine, when administered alone, will increase physiological 
measures. Administration of methamphetamine during d-amphetamine 
maintenance will increase heart rate and blood pressure, but will be safe and 
well-tolerated. 
Chapter Four. Method 
The proposed experiment and informed consent document were approved by 
the Institutional Review Board of the University of Kentucky Medical Center. 
Participants 
Eight participants who reported stimulant dependence were recruited through 
the use of flyers, newspaper, online and radio ads, and by word of mouth for 
participation in this experiment. Prior to enrollment in the experimental protocol, 
all participants were screened using health-history, drug-use history, and 
psychiatric history questionnaires. Questionnaires included: the Beck Depression 
Inventory (BDI), Brief Symptom Index (BSI), assessments for attention deficit 
hyperactivity disorder (ADHD), mental status, and drug and alcohol dependence. 
Drug histories were collected including time since first use, frequency and 
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quantity of use, and drugs used over the lifetime. Laboratory values were 
collected for all participants, including a complete blood count and chemistry 
panel, urinalysis, and electrocardiogram (ECG). Laboratory values outside of the 
normal range were reviewed by Dr. Lon R. Hays (University of Kentucky, 
Department of Psychiatry) or Dr. Paul E. A. Glaser (University of Kentucky, 
Department of Psychiatry) to determine if the levels were clinically significant 
before admittance into the study. ECGs were interpreted by Dr. John Gurley 
(University of Kentucky, Department of Cardiology) and any participant with an 
ECG determined to be abnormal was excluded from participation from the study. 
Participants with a history of clinically significant medical conditions, CNS 
disorders, impaired heart functions, history of chronic pulmonary obstructive 
disease, history of seizures, family history of sudden death, or any 
contraindications to the administration of stimulant medications (e.g. allergic 
reaction to stimulant medications or heart problems) were excluded from 
participation. Also, participants with a current or past history of psychiatric illness 
that in the opinion of the study physicians would interfere with performance were 
excluded from participation. All participants were physically and psychologically 
healthy, as determined by the medical staff, and were within 20% of their ideal 
body weight (BMI tables). 
Payment and Follow-Up 
Participants earned $80 for each experimental session, with $40 being paid 
for each session completed and $40 paid as a bonus if all sessions were 
completed. Participants also had the opportunity to earn approximately $6 on the 
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Balloon Analog Risk Task (BART) completed twice on each cognitive testing day 
and once during each experimental session (shown in Tables 1 and 2). In total, 
participants were able to earn approximately $2000. At the end of their 
participation, participants returned to the Laboratory of Human Behavioral 
Pharmacology (LHBP) and received a check for up to $500 once per week until 
they were paid all of the money they earned. When participants received their 
weekly payments, they also completed a brief follow-up to assess recent drug 
use. These data were not analyzed as part of the proposed study, but were 
collected in case future analyses look for changes in drug use after enrollment in 
a study. During this assessment, participants provided an expired breath sample 
to test for the presence of alcohol as well as provided a urine sample to test for 
the presence of illicit substances. 
General Procedures 
Prior to admission to the Clinical Research Development and Operations 
Center (CR-DOC) and before all study sessions (cognitive and experimental), 
participants provided a urine sample that was tested for the presence of drugs of 
abuse. Urine samples were tested using the Integrated E-Z Split Key Cup 
(Iminia, Los Angeles, CA) and Fastect Drug Screen Dipstick Test MTH 300 and 
OXY 100 (Branan Medical Corp., Irvine, CA) to test for the presence of 
amphetamines, barbiturates, benzodiazepines, cocaine, methadone, 
methamphetamine, opiates, oxycodone, PCP, and THC. Participants who 
provided a urine sample positive for drugs other than cocaine or THC were not 
admitted at that time. On session days, urine samples could test positive for 
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THC, amphetamines, or methamphetamine, depending on marijuana use prior to 
admittance or drugs administered during study sessions on previous days and 
were evaluated by Dr. William Stoops to determine if the study session could 
continue as planned. Any participant, who provided a urine sample that tested 
positive for a drug that was not administered as part of the study protocol, was 
discharged from the study. Expired breath samples were collected to assess for 
the presence of alcohol using a hand-held Alcosensor (Intoximeters, St. Loius, 
MO). Also, participants were asked to complete a sobriety test and participants 
who passed the sobriety test were allowed to participate in the day’s session. 
Female participants were required to use an effective form of birth control 
prior to admittance to the CR-DOC and received a pregnancy test using a urine 
HCG test (confirms II, I.M. Isbell Marthé Diagnostics, Inc., Naples, FL) prior to 
admittance to the CR-DOC as well as before every study session. Any female 
participant who tested positive for pregnancy was discharged from the study. 
Participants resided at the CR-DOC for approximately 28 days and completed 
one practice and eight experimental sessions. Participants had a full day to 
acclimate prior to beginning maintenance medications. Timeline for maintenance 
medications and sessions are shown in Table 1. Participants were informed that 
during the study they would be given medications that may be placebo or an FDA 
approved prescription stimulant, such as d-amphetamine or methamphetamine. 
Participants were informed that the purpose of the study was to see how the 
drugs affect mood and behavior, if they like the drug and would be willing to take 
it again, and the affect of the drugs on cognitive and performance tasks. 
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Participants were not informed of the specific drugs they received, possible 
outcomes, or performance expectations. 
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Table 1. Timeline for maintenance medications and sessions 
Day 1   Admission to CR-DOC 
Day 2   Practice Session 
Days 3-24 Drug maintenance. Doses administered at 0700 and 1900 
daily 
Day 9 Cognitive and performance task battery completed twice 
Days 10-13 Experimental Sessions (timeline shown in Table 2) 
Day 20 Cognitive and performance task battery completed twice 
Days 21-24 Experimental Sessions (timeline shown in Table 2) 
Day 25 Discharge 
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Practice session. Participants completed a practice session prior to beginning 
maintenance medication to familiarize them with the behavioral tasks, 
progressive ratio, and timeline of experimental sessions, which are described 
below. No medications were administered during the practice session. 
Instructions for practice session. Today, you will not receive any medications, 
but will periodically complete behavioral tasks to familiarize you with the study 
routine. One of these tasks will be the progressive ratio task that you will do in 
experimental sessions to earn drug. The number of responses required for 
completing each of the opportunities to earn drug will increase as you 
proceed in the task. You will have to complete the full task today. In the 
future, you will decide how much of the task you want to complete to earn 
intranasal drug. 
Experimental sessions. Participants completed four experimental sessions 
after at least 7 days of maintenance in each maintenance condition. Participants 
completed a pre-session task at 0900 and at 0930 sampled intranasally the 
medication that they had the opportunity to work for later in the session. 
Participants completed subject-rated drug-effects questionnaires at 0945 and 
1000. Between 1005 and 1100, participants completed an abbreviated cognitive 
battery (visual probe, cued go/no-go, and BART). Then participants completed 
the subject-rated drug-effects questionnaires again at 1100 and 1130, followed 
by a break from 1145 until 1330. During the break, participants were allowed to 
eat lunch and engage in any desired activities, except smoking. At 1330 
participants’ vitals were recorded and the self-administration portion of the 
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session began. Between 1345 and 1430 participants completed the progressive 
ratio and subject-rated drug-effects questionnaires. At 1430 the participants 
received the dose that they worked for in the progressive ratio and completed 
subject-rated drug-effect questionnaires every 15 minutes for the next hour. After 
1530, participants completed the subject-rated drug-effect questionnaires every 
30 minutes for another hour. A timeline of experimental sessions is illustrated in 
Table 2. It is possible that two participants were enrolled in the study 
simultaneously and participants were instructed not to discuss drug effects with 
any other participants. 
Instructions for medication-administration during sampling. You will now 
receive a drug. Please pay attention to how the drug makes you feel, because 
later today you will be given the opportunity to earn all, some or none of this 
drug. The drug will be in the form of a powder. Please follow along with the 
research assistant as he/she reads the instructions for you for preparing the 
powdered medication. 
1) The nurse will empty the powdered medication on the mirror for you. 
2) With the single-edged razor blade, please separate the powdered medication 
into two (2) lines that are approximately equal in volume.  
3) When told to do so by the research assistant and nurse, please use the straw 
to inhale or snort one of the “lines” into each of your nostrils. 
4) You will have a total of two (2) minutes to inhale or snort the drug. 
Instructions for medication administration during self-administration. You will 
now have the opportunity to work for the drug you sampled this morning. 
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Please refer to your notes about the drug effects from the previous session 
because today you will be able to work for all, or some, of the drug from this 
morning.  
You will have a total of ten (10) opportunities to respond by clicking on a 
mouse to receive the drug from this morning, and can earn the full dose from 
this morning’s session. As you complete each segment, you will earn 1/10th of 
the drug. The total amount of drug that you earn today will be given to you all 
at once when you are done. 
You should understand that you do not have to work for any drug today. 
However, if you choose not to work for any drug, you will not receive any drug 
today. You should also understand that you can stop working at any time. 
However, if you start a segment on the computer and do not finish it, you will 
only receive the total drug that you earned by completing earlier segments. 
Whether or not you choose to work for drug, you will have to complete the 
rest of the 3-hour session. 
Baseline cognitive testing. Participants completed a baseline testing session, 
which served as a practice session to familiarize them with the battery of 
cognitive and performance tasks that were administered during the maintenance 
cognitive testing days. Baseline study sessions followed the same timeline and 
procedures as the maintenance cognitive testing days, except they were 
conducted at the Laboratory of Human Behavioral Pharmacology, rather than the 
CR-DOC inpatient unit. No medications were administered.  
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Maintenance cognitive testing. Participants completed the cognitive battery at 
0830 and 1300 or 1000 and 1430, with the participant completing the battery at 
the same pairing of times on each testing day. Maintenance testing was 
conducted on the last day of maintenance before study sessions began for each 
maintenance condition (0 mg d-amphetamine and 40 mg d-amphetamine). The 
cognitive battery consisted of the grooved pegboard task, visual probe task, cued 
go/no-go task, n-back, cocaine Stroop task, balloon analog risk task (BART), and 
digit symbol substitution task (DSST). 
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Table 2. Experimental Session Timeline 
0830  Vitals, sobriety test, pre-session paperwork completed 
0900  Pre-session subject-rated drug-effects, vitals recorded 
0930 Sample dose administered, subject-rated drug-effects, vitals 
recorded 
0945  Subject-rated drug-effects, vitals recorded 
1000  Subject-rated drug-effects, vitals recorded 
1005 Abbreviated cognitive battery, vitals recorded after each task 
1100  Subject-rated drug-effects, vitals recorded 
1130  Subject-rated drug-effects, vitals recorded 
1145  Participant had a 2 hour break 
1330  Vitals recorded 
1345 Progressive ratio, pre-dose subject-rated drug-effects, vitals 
recorded 
1430 Dose administered, subject-rated drug-effects, vitals recorded 
1445  Subject-rated drug-effects, vitals recorded 
1500  Subject-rated drug-effects, vitals recorded 
1515  Subject-rated drug-effects, vitals recorded 
1530  Subject-rated drug-effects, vitals recorded 
1600  Subject-rated drug-effects, vitals recorded 
1630  Subject-rated drug-effects, vitals recorded   
 
 
27 
Modified Progressive-Ratio Procedure 
The modified progressive-ratio procedure has been used in previous studies 
and has been shown to be a reliable measure of human drug reinforcement 
(Comer, Collins, & Fischman, 1997; Comer, Collins, MacArthur, Fischman, 1999; 
Comer, Collins, Wilson, Donovan, Foltin, & Fischman, 1998; Rush, Essman, 
Simpson, & Baker, 2001; Stoops, 2008). During the self-administration portion of 
each experimental session participants had 10 opportunities to work to earn a 
portion of the drug sampled that morning. Participants were presented with the 
progressive-ratio task on a computer screen and they were instructed to use the 
computer mouse to click on a button to work to earn a portion of the drug, each 
completed ratio earned 1/10th of the sampled dose. Participants were instructed 
that they might choose to work to earn all, a portion of, or none of the sampled 
dose. To complete the first ratio, participants were required to click 400 times and 
each additional ratio increased by 100 (i.e. 500, 600, 700, 800, 900, 1000, 1100, 
1200, and 1300). To earn all of the sampled dose, participants were required to 
click a total of 8500 times. The participant was allowed quit the task at any time if 
they clicked a button labeled stop and the task was terminated. They received 
the dose for the highest ratio that was completed. This was verified by a research 
assistant in the data file for the task. Data was collected on the breakpoint (i.e. 
the highest ratio that was completed).  
For each ratio completed the participant earned 1/10th of the drug that was 
sampled that morning. The doses of methamphetamine were mixed with lactose 
monohydrate powder, N.F. so that all doses were 60 mg of powder. After taking 
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the self-administered dose intranasally, participants completed the subject-rated 
drug-effect questionnaires every 15 minutes for the first hour then every 30 
minutes for another hour. If the participant chose not to work for any of the 
sampled dose they still completed the scheduled tasks, which eliminated the 
possibility of a participant choosing no drug to end a session early. All sessions 
were conducted as shown in Table 1, regardless of the drug dose earned.  
Subject-Rated Drug-Effect Questionnaires 
All of the subject-rated drug-effect questionnaires were administered using an 
Apple microcomputer with a mouse attached in a fixed order. Participants 
completed the tasks as indicated on the daily schedule in Table 1 during 
experimental sessions.  
Adjective Rating Scale. The adjective rating scale is a measure that consists 
of 32 questions divided into two subscales: sedative and stimulant. Participants 
were shown questions on a computer screen and were asked to indicate their 
answer by using a computer mouse to select one of 5 buttons: “not at all,” “A little 
bit,” “moderately,” “quite a bit,” or “extremely” (scored as 0-4 respectively). The 
sedative subscale consists of the following adjectives: Clumsy, Dizzy, Confused, 
Dazed, Sleepy, Depressed, Difficulty Walking, Drowsy, Nausea, Drunk, Fatigued, 
Lazy, Relaxed, Tired, Sluggish, and Spaced Out.  The stimulant subscale 
consists of the following adjectives: Active, Alert, Irregular Heartbeat, Good 
Mood, Muscles Twitching, Agitated, Energetic, Excited, Euphoric, Irritable, 
Nervous, Restless, Shaky, Sweaty, Talkative, and Heart Racing. Composite 
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scores were produced for each subscale, with a maximum score of 64 on each 
subscale. 
Visual Analog Scale (True/False). The Visual Analog Scale (VAS) True/False 
is a measure of subject-rated drug-effects. Participants were presented with 
statements and a sliding scale that is 101 mm long on a computer screen. The 
sliding scale was labeled “false” on the left and “true” on the right and participants 
were asked to indicate how much they agree with the statement presented by 
using a computer mouse to place a marker on the scale. Each item was scored 
as how many millimeters the participant placed the marker from the end of the 
scale indicating false (i.e. “false” would be scored as 0 and “true” would be 
scored as 100). The maximum possible score was 100 for any item. The 
statements presented were as follows: “Is the drug producing any effect right 
now?; Is the drug producing any bad effects right now?; Is the drug producing 
any good effects right now?; Is the drug making you feel high right now?; Are you 
experiencing a rush from the drug right now?; How much do you like the drug 
right now?; Is the drug making you feel stimulated right now?; Is the drug 
impairing your performance right now?; Is the drug improving your performance 
right now?; Based on how the drug effect feels right now, would you be willing to 
take this drug again?; Based on how the drug effect feels right now, would you 
be willing to pay for this drug?; Is the drug making you  feel active, alert or 
energetic right now?; Is the drug making you feel shaky or jittery right now?; Is 
the drug making you feel euphoric right now?; Is the drug making you experience 
an irregular or racing heartbeat right now?; Is the drug making you feel talkative 
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or friendly right now?; Is the drug making you feel nauseous, queasy, or sick to 
your stomach right now?; Is the drug making you feel nervous or anxious right 
now?; Is the drug making you feel restless right now?; Is the drug making you 
feel sluggish, fatigued or lazy right now? 
Cognitive and Performance Measures 
The cognitive measures were administered using the grooved pegboard, a 
Dell laptop computer (visual probe, cued go/no-go, n-back, cocaine Stroop, and 
BART), and an Apple Macintosh microcomputer (DSST) in a fixed-order. These 
measures were administered twice daily on cognitive testing sessions and an 
abbreviated battery (i.e. visual probe, cued go/no-go, and BART) was 
administered once during experimental sessions. These tasks have been 
validated and used in previous studies (Brewer, Worhunsky, Carroll, Rounsaville, 
& Potenza, 2008; Gardini, Caffarra, & Venneri, 2009; Hester, Dixon, & Garavan, 
2006; Kaufman, Ross, Stein, & Garavan, 2003; Lejuez, et al., 2002; Liu, Lane, 
Schmitz, Waters, Cunningham, & Moeller, 2011; MacLeod, Mathews, & Tata, 
1986; Oliveria, Barroso, Silveira, Ponce, Vaz, & Nappo, 2009; Waters, Sayette, 
Franken, & Schwartz, 2005). 
Grooved Pegboard Task. The grooved pegboard task was an assessment of 
manual dexterity (Trites, 1977). Participants were presented with a pegboard that 
consists of a dish to hold the pegs, enough pegs to fill the pegboard with some 
extra, and a pegboard with 25 holes with the pegs oriented in varying directions. 
Participants were asked to use only their dominant hand and place the pegs into 
the pegboard as quickly as they could. Data was collected as a composite of the 
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number of holes filled on the pegboard, time to complete the task in seconds, 
and number of pegs dropped.  
Instructions for the grooved pegboard task. This is a pegboard and these are 
the pegs.  
All the pegs are the same. They have a groove, that is, a round side and a 
square side and so do the holes in the board. What you must do is match the 
groove of the peg with the groove of the board and put these pegs into the 
holes like this. (Demonstrate by filling the first row, then remove the pegs and 
return them to the tray) 
When I say go, begin here and put the pegs in the boards as fast as you can 
using only your dominant hand. Fill the top row completely from (right handed: 
left to right or left handed: right to left). Do not skip any: fill each row the same 
way you filled the top row. Any questions? Ready, as fast as you can, go. 
Visual Probe Paradigm. The visual probe paradigm measured attention bias 
toward salient images, such as images of a drug of abuse (MacLeod, Mathews, 
& Tata, 1986). Participants were presented pairs of images, either a cocaine 
image and a neutral image or two neutral images, oriented with one on the right 
side of the computer screen and one on the left. After a set period of time, the 
images disappeared and a target replaced one of the images. Participants were 
asked to identify which side of the screen the target appeared on by responding 
on one of two keys on a computer keyboard. Data were collected on reaction 
times when the target replaced a cocaine image and when the target replaced a 
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neutral image and the attention bias score was obtained by subtracting reaction 
times to cocaine images from reaction times to neutral images. 
Instructions for the visual probe task. This is a reaction task.  You will be 
presented with a fixation point (a tiny cross) at the center of the screen 
followed by a pair of images.  These are images of various objects.  Again, 
you are to look at the pictures while they are on the screen.  Once the images 
disappear from the screen, an X will appear on either the left or right side of 
the screen.  Your task is to respond as quickly as possible to the X by 
pressing the yellow key if the X is on the left side of the screen or the green 
key if the X is on the right side of the screen.  Once you make your response, 
another fixation point will appear followed by the presentation of a new set of 
images.  You will perform several of these trials. 
Cued Go/No-Go Task. The cued go/no-go task was a measure of inhibitory 
control (Miller, Schaffer, & Hackley, 1991). Participants were shown a cue, an 
outline of a rectangle, which was oriented either horizontally or vertically. The 
orientation of the rectangle signified it as a go or a no-go cue. Participants were 
asked to respond on a computer keyboard when the rectangle filled in green, but 
to inhibit responding when the rectangle filled in blue. For example, when a 
vertical rectangle was a go cue, 80% of the time it filled in green, which indicated 
to the participant that they should respond. However, 20% of the time go cues 
filled in blue, which required participants to inhibit responding after being primed 
to respond. Data were collected on the percent of responses that were correctly 
inhibited after being presented with a go cue. 
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Instructions for the cued go/no-go task. This is a reaction time task that I 
would like you to perform. While you are performing the task you sit in front of 
the computer screen just you as are doing. You place your index finger on the 
‘?’ key. 
Presented on the screen will be rectangular boxes that are standing upright or 
lying flat.   
The boxes are empty when they first appear on the screen.  If the box turns 
green then you are to press the ‘?’ button as quickly as possible.  If the box 
turns blue then no response is required. 
Now, before a box appears, you will see a plus sign in the middle of the 
screen. It serves as a fixation point so that you know where to focus your 
attention on the computer screen. After the plus sign disappears, a box will 
appear on the screen. Again, if the box turns green, respond as quickly as 
possible by pressing the ‘?’ key.  If the box turns blue then no response is 
required.   
To help you respond quickly, the computer will display how fast you are 
pressing the key when the green target appears.  Once you respond to a 
green target, the screen will show the amount of time it took for you to make 
that response.  The time is presented in milliseconds.  The fewer the 
milliseconds, the faster the response.  So lower numbers are better. If you 
accidentally respond to a blue target, the screen will say “Incorrect 
Response”. 
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N-Back Task. The N-Back task assessed working memory by asking 
participants to identify if letters presented on a computer screen were the same 
or different than previous letters in a specific pattern (Kirchner, 1958). The task 
consisted of three pattern conditions: one back, two back, and three back. In one 
back, participants were asked to respond to each letter presented on the 
computer screen to identify if it was the same as the letter immediately before the 
letter presented or not the same. Two back required participants to respond if the 
current letter was the same as or different than the letter presented two letters 
before. Finally, the three back required participants respond to identify if the 
current letter was the same as or different than the letter presented three letters 
before. Data was collected on reaction time and accuracy to letters that are 
targets (i.e. the same as) and not-targets (i.e. different than) for each of the 
conditions.  
Instructions for the n-back task. You will see letters on the screen, one letter 
at a time.  
When the letter on-screen matches the last letter presented (two letters back 
for two back or three letters back for three back), press TARGET (1). 
When the letter on-screen is not the same as the letter that came before it, 
press NOT A TARGET (2).  
Cocaine Stroop Task. The cocaine Stroop task was a modified version of the 
Stroop task, which required participants to identify the color of cocaine words and 
neutral words (Hester, Dixon, & Garavan, 2006; Liu, Lane, Schmitz, Waters, 
Cunningham, & Moeller, 2011). Participants were presented words that are either 
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blue, red, or green and they were asked to identify the color of the text by 
pressing a key on a computer keyboard. Data were collected on the reaction time 
to respond to neutral and cocaine words and an attention bias score was 
obtained by subtracting the reaction time to cocaine words from the reaction time 
to neutral words.  
Instructions for the cocaine Stroop task. In this task you will be presented with 
words that are either red, blue, or green. You will be asked to respond on the 
keyboard with the color that the word is written in.  
For red text respond with the number 1 (red dot) 
For blue text respond with the number 2 (blue dot) 
For green text respond with the number 3 (green dot) 
Balloon Analog Risk task. The balloon analog risk task (BART) was a 
measure of risk taking (Lejuez et al., 2002). Participants were presented with a 
screen where they can click a computer mouse to pump a balloon, each trial 
consisted of 20 balloons and each pump was worth $0.01. Each time the 
participant clicked the mouse, $0.01 was added to a temporary bank, and at any 
time participants may choose to end a balloon and save their earnings in a 
permanent bank, which was paid to them at the end of the session. Participants 
were instructed that they could pump the balloon as many times as they chose, 
but that the balloon may pop after as few as one or two clicks or could fill the 
screen, and if the balloon pops they lose all of the money stored in their 
temporary bank. Data were collected on the percentage of balloons that pop. 
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Instructions for the balloon analog risk task. Now you are going to see 20 
balloons, one after another, on the screen. For each balloon, you will use the 
mouse to click on the box that will pump up the balloon. Each click on the 
mouse pumps the balloon up a little more.  
BUT remember, balloons pop if you pump them up too much. It is up to you to 
decide how much to pump up each balloon. Some of these balloons might 
pop after just one pump. Others might not pop until they fill the whole screen. 
You get MONEY for every pump. Each pump earns 1 cent(s). But if a balloon 
pops, you lose the money you earned on that balloon. To keep the money 
from a balloon, stop pumping before it pops and click on the box labelled 
“Collect $$$”. 
After each time you collect $$$ or pop a balloon, a new balloon will appear.  
At the end of the experiment, you will be paid the amount earned on the 
game. 
Digit-Symbol Substitution Task (DSST). A computerized version of the DSST 
was used in this experiment (McLeod, Griffiths, Bigelow, & Yingling, 1982). 
Participants used a numeric keypad to reproduce patterns that were associated 
with one of nine patterns associated with numbers shown on the computer 
screen. Participants had 90 seconds to enter as many patterns as possible. Data 
were collected on the number of patterns attempted and number of patterns 
correctly entered. 
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Physiological Measures 
Heart rate, blood pressure, temperature, and heart rhythmicity (via ECG) 
were measured using a Dinamap digital monitor (Critikon, Pro 1000, Tampa, FL). 
Vitals were collected during experimental sessions every 30 minutes for 1.5 
hours before medication administration starting at 0830 and then every 15 
minutes until the participant went on break at 1145. After the break, vitals were 
recorded at 1330, 1345, and 1430 followed by the self-administered dose. Vitals 
were then recorded every 15 minutes until 1530 and after that they were 
recorded every 30 minutes until 1630.  
Drug Administration 
All medications were administered in a double blind fashion, such that the 
nurses, research assistant, and participant were not aware of the dose that is 
being given. Dr. Stoops determined the dose order so that the nurse and 
research assistant were not aware of the dose order. Maintenance medications 
were prepared by over-encapsulating a commercially available 5 mg d-
amphetamine spansule and loose filling the capsule with lactose monohydrate 
powder, N.F. Participants received escalating doses of sustained release d-
amphetamine twice daily until the target dose of 40 mg per day is reached. 
Participants received 5 mg twice daily on the first day of d-amphetamine 
maintenance, 10 mg twice daily on the second and third days, and 20 mg twice 
daily for the remaining days. Placebo capsules were prepared in the same way 
as the d-amphetamine, except only contained lactose monohydrate powder, N.F. 
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Methamphetamine doses were prepared by weighing out the appropriate 
dose (0, 10, 20 or 30 mg) of methamphetamine and then were mixed with lactose 
monohydrate powder, N.F. to make a total of 60 mg of powder. Participants 
sampled the entire dose in the morning the session and had the opportunity to 
work for a portion of the sampled dose in the afternoon self-administration portion 
of the session. Sampled doses were divided into 10 parts for self-administration 
and were prepared into 10 vials that contained each of the possible doses that 
the participant may earn (i.e., 10% to 100% of the sampled dose). Each of the 
vials contained the appropriate tenth of methamphetamine powder and were 
mixed with lactose monohydrate powder, N.F. so that all doses consisted of 60 
mg of powder, regardless of the weight of methamphetamine. 
Data Analysis  
Statistical analysis was used to investigate drug effects on progressive-ratio 
task, subject-rated drug-effects questionnaires, performance tasks, cognitive 
tasks, and physiological indices. For all statistical analyses, effects with p ! .05 
were considered significant.  
Progressive ratio. Data from the progressive-ratio task were analyzed using a 
two-factor repeated-measures analysis of variance (ANOVA). The factors were 
d-Amphetamine (i.e., 0 or 40 mg/day) and Methamphetamine (i.e., 0, 10, 20, and 
30 mg). F statistics were used to interpret the ANOVA outcomes. During self-
administration sessions, participants determined the amount of drug that they 
ingested. Thus, varying amounts of drug was administered to participants during 
the self-administration session. Due to participants ingesting varying amounts of 
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drug, data from subject-rated drug-effects questionnaires, performance 
measures, and physiological indices were not statistically analyzed. 
Subject-rated drug-effects and physiological indices. Two analyses were 
conducted to analyze subject-rated drug-effect and physiological data. First, 
peak-effect data, which is the maximum response reported during data collection 
for that session, were calculated for each participant. Second, data were 
analyzed as area-under-the-time-action curve (AUC), which was calculated for 
each participant using the trapezoidal method. Peak effect and AUC were 
analyzed in the same fashion as breakpoint data from the progressive ratio task.  
Cognitive Performance During Methamphetamine Challenge. Cognitive data 
collected during experimental sessions were analyzed in the same fashion as the 
break-point data. 
Cognitive Performance During Maintenance. Cognitive data collected from 
each of the tasks, excluding the N-Back Task, during each of the maintenance 
conditions were analyzed using a t-test to compare placebo and d-amphetamine 
(40 mg/day). For these analyses, the data were averaged across time (i.e., 
morning and afternoon). The N-Back Task was analyzed using a three-factor 
repeated-measures ANOVA with d-Amphetamine (i.e., 0 or 40 mg/day), Time 
(i.e., morning or afternoon), and Trial (i.e., one-, two-, or three-back) as factors. 
Power Analysis 
In a previous study from our laboratory, we assessed cocaine choice during 
d-amphetamine and placebo maintenance (Rush et al., 2010). During d-
amphetamine maintenance, subjects made significantly fewer choices for 20 mg 
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intranasal cocaine relative to placebo maintenance. That study enrolled 9 
subjects, which was sufficient to detect the small effect size (f=0.16) for d-
amphetamine to reduce the reinforcing effects of cocaine. Enrolling a similar 
number of subjects (n=8) was estimated to provide us with sufficient power to 
detect a significant effect of d-amphetamine on methamphetamine choice, which 
was the primary outcome variable for this study. 
Chapter Five. Results 
Methamphetamine Self-Administration During d-Amphetamine Maintenance 
Progressive-Ratio Responding. ANOVA revealed a significant main effect of 
methamphetamine on number of doses earned. Methamphetamine dose-
dependently increased the number of doses earned regardless of the 
maintenance condition (Figure 1). There were no other significant effects on 
number of doses earned. 
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Figure 1. 
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Subject-Rated Effects of Methamphetamine During d-Amphetamine 
Maintenance 
Adjective Rating Scale 
Peak Effect. ANOVA revealed only a main effect of methamphetamine for 
scores on the Stimulant scale of the Adjective Rating Scale. Methamphetamine 
increased these scores as function of dose regardless of the maintenance 
condition. There were no significant effects on the Sedative scale of the Adjective 
Rating Scale. F-values and means are shown in Tables 3 and 4, respectively.  
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Table 3. F-values from peak-effect analysis for physiological indices and subject-
rated drug-effects measures (Bold indicates a significant F-value).  
Outcome 
Measures 
 
d-AMPH  
 
METH  
METH x  
d-AMPH 
Physiological    
Diastolic Pressure 1.8 1.9 0.5 
Heart Rate 1.8 1.2 0.6 
Mean Arterial Pressure 4.1 3.4 0.0 
Systolic Pressure 8.6 4.4 1.1 
Temperature 0.8 0.2 0.3 
    
Adjective Rating Scales    
Sedative 2.1 0.4 0.4 
Stimulated 3.1 8.9 1.1 
    
Visual Analog Scales    
Active/Alert/Energetic 1.6 5.3 0.7 
Any Effects 7.4 10.5 0.5 
Bad Effects 0.4 2.6 0.3 
Euphoric 4.6 2.7 2.0 
Good Effects 10.4 9.8 0.6 
High 5.8 9.2 0.3 
Irregular Heartbeat 5.5 5.3 1.8 
Like Drug 13.9 9.8 0.6 
Nauseous/Sick to Stomach 4.4 2.3 1.7 
Nervous/Anxious 1.8 2.1 0.9 
Pay For 10.7 6.2 0.9 
Performance Impaired 2.6 2.9 1.9 
Performance Improved 3.8 2.0 0.4 
Restless 4.2 2.5 1.6 
Rush 13.4 5.8 0.1 
Shaky/Jittery 3.8 3.4 3.6 
Sluggish/Fatigued/Lazy 2.3 1.8 1.3 
Stimulated 6.2 6.1 0.5 
Talkative/Friendly 2.2 3.2 0.6 
Willing to Take Again 5.6 9.3 1.2 
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Table 4. Peak means for physiological indices and subject-rated drug-effects   
              measures (Means [SEM]). 
Peak  d-Amphetamine (0 mg) 
Outcome 
Measures 
 
Placebo 
METH 
10 mg 
METH 
20 mg 
METH 
30 mg 
Physiological     
Diastolic Pressure 80.8 (3.7) 83.1 (2.8) 81.5 (1.5) 83.9 (3.4) 
Heart Rate 79.2 (3.8) 85.9 (5.0) 83.5 (4.9) 87.0 (3.6) 
Mean Arterial Pressure 94.2 (3.3) 99.9(2.1) 98.2 (1.7) 100.8 (2.7) 
Systolic Pressure 120.5 (3.7) 133.0 (3.9) 131.5 (1.8) 133.1 (3.9) 
Temperature 98.1 (0.2) 98.1 (0.2) 98.0 (0.2) 98.0 (0.1) 
     
Adjective Rating Scale     
Sedative 3.9 (1.3) 4.4 (1.2) 3.4 (1.2) 4.4 (1.6) 
Stimulated 6.8 (2.6) 10.9 (1.9) 11.8 (1.8) 14.1 (2.2) 
     
Visual Analog Scale     
Active/Alert/Energetic 7.9 (3.1) 30.1 (11.0) 32.4 (12.3) 37.5 (12.1) 
Any Effect 6.1 (3.3) 29.9 (9.8) 34.2 (10.4) 46.2 (9.8) 
Bad Effect 2.1 (1.0) 2.6 (1.4) 3.9 (1.8) 5.4 (2.6) 
Euphoric 2.0 (0.8) 6.6 (4.0) 5.8 (2.8) 17.8 (8.8) 
Good Effect 5.8 (3.2) 30.4 (9.5) 34.1 (10.7) 44.2 (9.7) 
High 6.5 (3.3) 29.2 (9.5) 33.0 (10.4) 42.5 (9.8) 
Irregular/Racing Heartbeat 2.9 (1.2) 5.9 (2.7) 7.4 (5.6) 22.5 (8.9) 
Like Drug 6.8 (2.9) 36.0 (10.4) 39.1 (11.0) 44.8 (10.0) 
Nauseous/Sick to Stomach 3.8 (1.4) 8.5 (3.4) 5.0 (2.2) 9.1 (3.7) 
Nervous/Anxious 2.6 (1.1) 11.4 (7.7) 4.8 (2.5) 13.6 (6.6) 
Pay For 4.6 (2.3) 30.5 (10.9) 31.2 (12.6) 39.2 (12.2) 
Performance Impaired 2.4 (1.0) 6.1 (3.0) 5.2 (2.8) 22.4 (11.3) 
Performance Improved 6.0 (2.8) 21.2 (11.3) 21.2 (12.5) 19.6 (11.2) 
Restless 2.1 (0.7) 7.5 (2.5) 9.4 (4.4) 11.1 (4.0) 
Rush 5.0 (2.9) 23.1 (10.0) 28.0 (10.8) 34.0 (11.3) 
Shaky/Jittery 2.2 (0.9) 26.1 (11.4) 5.2 (2.6) 21.9 (8.7) 
Sluggish/Fatigued/Lazy 4.8 (2.2) 10.4 (6.4) 11.6 (6.6) 11.1 (5.8) 
Stimulated 7.1 (3.7) 27.2 (10.0) 28.9 (11.0) 35.8 (10.6) 
Talkative/Friendly 13.2 (5.4) 31.4 (11.8) 30.5 (12.5) 38.8 (12.9) 
Willing to Take Again 6.2 (2.8) 45.0 (13.0) 47.0 (13.6) 53.1 (12.1) 
 
 
 
 
45 
Table 4 (continued). Peak means for physiological indices and subject-rated 
drug effects measures  (Means [SEM]). 
Peak  d-Amphetamine (40 mg) 
Outcome 
Measures 
METH 
0 mg 
METH 
10 mg 
METH 
20 mg 
METH 
30 mg 
Physiological     
Diastolic Pressure 75.4 (3.6) 82.5 (2.0) 80.6 (2.0) 81.8 (2.5) 
Heart Rate 86.9 (3.2) 88.0 (4.3) 84.0 (3.1) 88.4 (4.1) 
Mean Arterial Pressure 91.1 (2.6) 97. 0 (1.7) 95.8 (2.1) 97.9 (2.2) 
Systolic Pressure 119.6 (2.1) 125.1 (3.1) 125.0 (2.3) 128.0 (2.4) 
Temperature 97.9 (0.2) 98.0 (0.2) 98.0 (0.1) 97.9 (0.2) 
     
Adjective Rating Scale     
Sedative 2.1 (0.6) 3.0 (0.9) 3.2 (1.1) 4.0 (1.2) 
Stimulated 6.2 (1.8) 9.2 (2.0) 9.8 (1.8) 10.2 (1.9) 
     
Visual Analog Scale     
Active/Alert/Energetic 11.5 (7.3) 22.4 (11.3) 29.4 (9.0) 31.2 (9.5) 
Any Effect 3.8 (1.4) 20.1 (11.4) 26.9 (7.0) 33.8 (7.0) 
Bad Effect 1.9 (1.0) 2.8 (1.4) 2.9 (1.2) 4.6 (2.1) 
Euphoric 2.1 (1.0) 4.2 (2.7) 5.8 (3.7) 7.5 (4.2) 
Good Effect 3.8 (1.5) 18.4 (11.7) 25.8 (7.4) 34.5 (7.6) 
High 4.1 (1.6) 20.8 (11.5) 27.9 (7.3) 33.5 (7.3) 
Irregular/Racing Heartbeat 1.9 (0.7) 3.5 (1.5) 4.1 (1.7) 6.9 (2.9) 
Like Drug 3.5 (1.3) 21.2 (11.2) 29.2 (8.7) 35.2 (7.9) 
Nauseous/Sick to Stomach 2.4 (0.9) 4.2 (2.0) 4.6 (2.5) 5.6 (2.2) 
Nervous/Anxious 2.6 (1.2) 5.2 (2.6) 4.0 (2.5) 7.6 (4.1) 
Pay For 3.2 (1.4) 18.2 (11.2) 27.1 (9.0) 30.0 (9.3) 
Performance Impaired 2.2 (1.3) 3.1 (1.2) 5.0 (2.8) 5.1 (2.2) 
Performance Improved 2.6 (1.2) 13.8 (10.9) 14.8 (8.1) 15.6 (9.2) 
Restless 3.5 (1.6) 4.2 (1.4) 6.6 (3.2) 7.8 (3.1) 
Rush 1.6 (0.8) 16.0 (12.0) 20.8 (8.3) 28.4 (9.6) 
Shaky/Jittery 2.9 (1.2) 5.0 (2.3) 7.6 (3.9) 8.5 (4.1) 
Sluggish/Fatigued/Lazy 6.8 (4.2) 3.2 (1.3) 9.8 (5.7) 7.6 (3.8) 
Stimulated 3.6 (1.6) 17.5 (10.8) 25.0 (7.9) 26.6 (8.6) 
Talkative/Friendly 11.8 (7.8) 23.6 (12.8) 27.2 (10.0) 27.6 (10.2) 
Willing to Take Again 4.0 (1.8) 22.0 (11.6) 28.8 (9.2) 42.8 (11.8) 
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Area-Under-the-Time-Action Curve. Analyses of area-under-the-time-action 
curve data revealed a pattern of effects similar to those observed with analysis of 
peak effect data. F-values and means and for these analyses are shown in 
Tables 5 and 6. 
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Table 5. F-values from area-under-the-time-action curve analysis for 
physiological indices and subject-rated drug-effects measures (Bold 
indicates a significant F-value). 
 
Outcome Measures 
 
d-AMPH 
 
METH  
METH x  
d-AMPH 
Physiological    
Diastolic Pressure 0.9 0.4 0.3 
Heart Rate 0.9 0.4 0.3 
Mean Arterial Pressure 6.0 5.1 0.2 
Systolic Pressure 12.4 7.7 0.5 
Temperature 0.1 0.3 0.7 
    
Adjective Rating Scale    
Sedative 2.0 0.3 0.1 
Stimulated 3.4 10.5 2.9 
    
Visual Analog Scale    
Active/Alert/Energetic 5.5 5.0 0.2 
Any Effects 16.9 7.8 1.0 
Bad Effects 0.5 2.5 0.3 
Euphoric 4.5 2.6 2.4 
Good Effects 21.9 7.4 0.8 
High 11.3 7.0 0.7 
Irregular/Racing Heartbeat 7.0 7.5 1.8 
Like Drug 17.3 7.2 0.6 
Nauseous/Sick to Stomach 4.2 2.3 0.8 
Nervous/Anxious 1.6 2.0 2.1 
Pay For 9.4 4.9 0.7 
Performance Impaired 2.2 3.6 2.0 
Performance Improved 3.2 2.0 0.2 
Restless 6.2 2.4 1.4 
Rush 9.9 3.9 0.1 
Shaky/Jittery 2.2 3.1 3.6 
Sluggish/Fatigued/Lazy 2.2 1.9 1.2 
Stimulated 7.7 4.7 0.1 
Talkative/Friendly 6.8 3.5 0.6 
Willing to Take Again 12.3 7.9 0.8 
48 
Table 6. Means for area-under-the-time-action curve for physiological indices 
and subject-rated drug-effect measures (Means [SEM]). 
AUC  d-Amphetamine (0 mg) 
Outcome Measures Placebo METH  
10 mg 
METH  
20 mg 
METH  
30 mg 
Physiological     
Diastolic Pressure 75.9 (3.9) 77.1 (3.2) 77.9 (4.3) 79.5 (3.1) 
Heart Rate 75.9 (3.9) 77.1 (3.2) 77.9 (4.3) 79.5 (3.1) 
Mean Arterial Pressure 90.1 (2.8) 9.8 (1.9) 94.0 (1.4) 97.0 (2.9) 
Systolic Pressure 115.8 (2.9) 123.0 (2.8) 125.5 (2.1) 128.0 (3.2) 
Temperature 97.8 (0.2) 97.7 (0.2) 97.7 (0.2) 97.8 (0.1) 
     
Adjective Rating Scale     
Sedative 2.7 (0.8) 3.2 (0.9) 2.7 (0.9) 3.2 (1.2) 
Stimulated 5.5 (2.0) 8.8 (1.5) 10.0 (2.0) 12.2 (1.9) 
     
Visual Analog Scale     
Active/Alert/Energetic 6.1 (2.8) 22.2 (8.6) 25.9 (10.9) 30.3 (10.1) 
Any Effects 4.2 (2.5) 19.2 (6.5) 23.6 (8.9) 33.6 (8.1) 
Bad Effects 1.3 (0.6) 2.0 (1.1) 2.5 (1.3) 3.3 (1.5) 
Euphoric 1.3 (0.5) 4.1 (2.6) 4.0 (2.2) 10.0 (5.1) 
Good Effects 3.9 (2.2) 18.1 (6.7) 23.5 (9.1) 33.2 (7.7) 
High 4.1 (2.5) 19.1 (6.8) 23.6 (9.0) 32.0 (8.4) 
Irregular/Racing 
Heartbeat 
1.7 (0.7) 4.2 (2.0) 5.1 (2.5) 10.7 (3.3) 
Like Drug 3.9 (2.2) 22.9 (7.9) 28.4 (10.4) 34.7 (8.3) 
Nauseous/Sick to 
Stomach 
2.0 (0.8) 4.5 (1.6) 3.6 (1.7) 6.2 (3.0) 
Nervous/Anxious 1.6 (0.6) 4.2 (2.3) 3.2 (1.7) 10.0 (5.7) 
Pay For 2.4 (1.2) 21.6 (8.5) 25.6 (11.3) 30.6 (9.6) 
Performance Impaired 1.5 (0.7) 3.6 (1.9) 3.1 (1.7) 6.9 (2.8) 
Performance Improved 4.0 (2.0) 14.6 (8.2) 17.1 (10.7) 14.1 (8.1) 
Restless 1.5 (0.6) 4.8 (1.8) 6.4 (3.3) 6.9 (2.4) 
Rush 3.9 (2.5) 15.3 (7.4) 19.4 (9.8) 23.3 (7.9) 
Shaky/Jittery 1.5 (0.6) 7.9 (4.0) 3.4 (2.0) 13.5 (6.3) 
Sluggish/Fatigued/Lazy 3.3 (1.8) 8.6 (5.7) 7.8 (4.6) 8.2 (4.5) 
Stimulated 4.4 (2.5) 16.8 (7.3) 22.3 (9.6) 22.8 (7.1) 
Take Again 3.7 (2.1) 27.8 (8.4) 33.3 (10.5) 39.4 (9.2) 
Talkative/Friendly 7.1 (3.0) 22.5 (9.6) 25.6 (11.4) 29.7 (10.7) 
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Table 6 (continued). Means for area-under-the-time-action curve for 
physiological indices and subject-rated drug-effect 
measures (Means [SEM]). 
AUC  d-Amphetamine (0 mg) 
Outcome Measures Placebo METH  
10 mg 
METH  
20 mg 
METH  
30 mg 
Physiological     
Diastolic Pressure 80.5 (3.2) 80.5 (3.5) 78.3 (3.2) 81.2 (3.8) 
Heart Rate 80.5 (3.2) 80.5 (3.5) 78.3 (3.2) 81.2 (3.8) 
Mean Arterial Pressure 86.6 (2.6) 91.8 (2.1) 91.0 (1.8) 92.7 (2.2) 
Systolic Pressure 112.8 (2.4) 120.0 (3.2) 119.7 (2.0) 121.4 (2.2) 
Temperature 97.7 (0.2) 97.6 (0.2) 97.9 (0.2) 97.6 (0.2) 
     
Adjective Rating 
Scale 
    
Sedative 1.8 (0.5) 2.4 (0.9) 2.5 (0.8) 2.8 (0.6) 
Stimulated 6.0 (1.7) 7.6 (2.0) 8.5 (1.9) 8.2 (1.8) 
     
Visual Analog Scale     
Active/Alert/Energetic 3.9 (1.7) 18.0 (10.1) 21.9 (8.3) 22.8 (8.3) 
Any Effects 2.4 (1.0) 13.6 (9.1) 17.0 (6.4) 21.4 (6.4) 
Bad Effects 1.2 (0.6) 1.8 (0.9) 1.9 (0.8) 3.1 (1.5) 
Euphoric 1.4 (0.7) 2.8 (1.7) 3.4 (2.4) 3.6 (2.2) 
Good Effects 2.5 (1.0) 13.5 (10.2) 18.0 (6.6) 22.7 (6.7) 
High 2.6 (1.1) 14.8 (10.0) 18.3 (6.4) 21.0 (6.5) 
Irregular/Racing 
Heartbeat 
1.2 (0.5) 2.0 (0.8) 2.6 (1.0) 4.4 (1.7) 
Like Drug 2.4 (1.0) 15.9 (10.0) 21.1 (8.0) 24.2 (7.2) 
Nauseous/Sick to 
Stomach 
1.4 (0.5) 2.5 (1.3) 3.0 (1.5) 3.9 (1.6) 
Nervous/Anxious 2.0 (0.9) 2.5 (1.1) 2.8 (1.7) 4.6 (2.1) 
Pay For 2.2 (0.9) 13.4 (10.0) 21.0 (8.8) 21.2 (8.0) 
Performance Impaired 1.4 (0.7) 1.9 (0.8) 3.0 (1.7) 3.2 (1.4) 
Performance Improved 1.3 (0.6) 11.9 (10.1) 12.1 (7.2) 12.1 (8.0) 
Restless 2.4 (1.1) 2.5 (0.8) 3.9 (1.7) 4.5 (1.5) 
Rush 1.1 (0.5) 12.9 (10.3) 14.3 (6.4) 18.2 (7.6) 
Shaky/Jittery 2.2 (1.0) 2.9 (1.3)* 3.7 (1.9) 5.0 (2.4) 
Sluggish/Fatigued/Lazy 2.6 (1.4) 2.2 (0.9) 7.5 (5.0) 5.1 (2.8) 
Stimulated 2.4 (1.2) 10.9 (7.0) 17.8 (6.7) 18.2 (7.4) 
Take Again 2.2 (1.0) 18.0 (10.4) 21.8 (8.8) 29.7 (8.6) 
Talkative/Friendly 5.8 (3.0) 18.7 (10.9) 20.7 (9.2) 20.6 (9.0) 
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Visual Analog Scales 
Peak Effect. ANOVA revealed a significant interaction of methamphetamine 
and d-amphetamine for ratings of Shaky or Jittery  (Table 3). This interaction was 
attributable to 10 and 30 mg methamphetamine increasing these ratings above 
placebo levels during placebo maintenance but not during d-amphetamine 
maintenance (Table 4). 
ANOVA revealed a main effect of methamphetamine and d-amphetamine, but 
not an interaction of these factors, for ratings of Any Effect, Good Effects, High, 
Like Drug, Pay For, Rush, Stimulated, Talkative or Friendly and Willing to Take 
Again. Methamphetamine generally increased these ratings as a function of dose 
during both placebo and d-amphetamine maintenance. However, these ratings 
were lower during d-amphetamine maintenance relative to placebo maintenance. 
F-values and means are shown in Tables 3 and 4, respectively. Figures 2 and 3 
show data for two of these measures, ratings of Like Drug and Willing to Take 
Again, respectively. 
ANOVA revealed only a main effect of methamphetamine for ratings of 
Active, Alert, Energetic; Irregular or Racing Heartbeat; and Talkative or Friendly. 
Methamphetamine increased these ratings as function of dose regardless of the 
maintenance condition. F-values and means are shown in Tables 3 and 4, 
respectively. 
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Figure 2.  
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Figure 3. 
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Area-Under-the-Time-Action Curve. Analyses of area-under-the-time-action 
curve data revealed a pattern of effects similar to those observed with analysis of 
peak effect data. F-values and means and for these analyses are shown in 
Tables 5 and 6, respectively. 
Cognitive Effects of Methamphetamine During d-Amphetamine 
Maintenance 
Cued Go/No-Go Task. ANOVA revealed a significant interaction of 
methamphetamine and d-amphetamine for inhibitory failures to a no-go target 
following a no-go cue on the Cued Go/No-Go task (Table 7). This interaction was 
due to the methamphetamine having little effect during placebo maintenance, but 
dose-dependently increasing inhibitory failures during d-amphetamine 
maintenance (Table 8; Figure 4). There were no significant effects on inhibitory 
failures for a no-go target following a go cue or on reaction time to go targets 
following either go or no-go targets. 
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Table 7. F-values of cognitive tasks after methamphetamine administration (Bold 
indicates a significant F-value). 
Outcome Measures d-AMPH Dose METH Dose METH x 
d-AMPH 
Visual Probe Task    
Reaction Time Cocaine 0.0 0.4 0.0 
Reaction Time Neutral 0.0 0.6 0.6 
Attention Bias Score 0.0 0.0 1.7 
    
Cued Go/No-Go Task    
Reaction Time    
Go Cue 0.4 1.9 0.6 
No Go Cue 2.7 2.1 1.3 
Inhibitory Failures    
Go Cue 0.8 0.5 0.7 
No Go Cue 1.6 1.3 3.2 
    
Balloon Analog Risk Task    
Percent Exploded 0.6 0.9 1.8 
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Table 8. Means of cognitive tasks after methamphetamine administration (Means [SEM]). 
  d-Amphetamine (0 mg) 
Outcome Measures Placebo METH  
10 mg 
METH  
20 mg 
METH  
30 mg 
Visual Probe Task     
Reaction Time Cocaine 396.6 (32.5) 391.6 (26.3) 378.5 (25.0) 392.1 (29.5) 
Reaction Time Neutral 406.6 (33.4) 393.6 (28.2) 397.4 (31.4) 402.8 (26.9) 
Attention Bias Score 10.0 (11.6) 2.0 (6.1) 18.9 (7.7) 10.6 (12.7) 
     
Cued Go/No-Go Task     
Reaction Time     
Go Cue 291.8 (16.0) 285.6 (12.6) 280.0 (6.5) 285.6 (9.4) 
No Go Cue 328.4 (17.4) 326.9 (13.2) 326.5 (14.9) 322.2 (12.8) 
Inhibitory Failures     
Go Cue 0.1 (0.0) 0.2 (0.0) 0.2 (0.0) 0.2 (0.0) 
No Go Cue 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 
     
Balloon Analog Risk Task     
Percent Exploded 0.4 (0.0) 0.3 (0.0) 0.4 (0.0) 0.3 (0.0) 
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Table 8 (continued). Means of cognitive tasks after methamphetamine administration (Means [SEM]). 
 d-Amphetamine (40 mg) 
Outcome Measures METH  
0 mg 
METH  
10 mg 
METH  
20 mg 
METH  
30 mg 
Visual Probe Task     
Reaction Time Cocaine 393.5 (30.2) 388.0 (20.3) 382.4 (22.7) 389.9 (30.1) 
Reaction Time Neutral 403.2 (31.0) 408.9 (18.3) 381.0 (23.9) 399.7 (30.6) 
Attention Bias Score 9.7 (6.3) 20.9 (9.1) -1.3 (6.2) 9.8 (5.9) 
     
Cued Go/No-Go Task     
Reaction Time     
Go Cue 299.3 (20.7) 284.4 (10.5) 274.9 (8.1) 274.7 (5.1) 
No Go Cue 337.8 (22.8) 314.0 (16.1) 312.9 (16.3) 311.6 (13.4) 
Inhibitory Failures     
Go Cue 0.2 (0.1) 0.2 (0.0) 0.2 (0.0) 0.2 (0.1) 
No Go Cue 0.0 (0.0) 0.0 (0.0) 0.1 (0.0) 0.1 (0.0) 
     
Balloon Analog Risk Task     
Percent Exploded 0.3 (0.0) 0.3 (0.0) 0.3 (0.0) 0.3 (0.0) 
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Figure 4. 
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Visual Probe Task. There were no significant effects on the Visual Probe task. 
F-values and means for this task after the administration of methamphetamine 
are shown in Tables 7 and 8, respectively. 
Balloon Analog Risk Task (BART). There were no significant effects on the 
BART. F-values and means for this task after the administration of 
methamphetamine are shown in Tables 7 and 8, respectively. 
Physiological Effects of Methamphetamine During d-Amphetamine 
Maintenance 
Peak Effect. ANOVA revealed a main effect of methamphetamine and d-
amphetamine, but not an interaction of these factors, for systolic blood pressure 
(Figure 5). Methamphetamine generally increased systolic blood pressure as a 
function of dose during placebo and d-amphetamine maintenance. The pressure-
increasing effects of methamphetamine on systolic blood pressure were 
attenuated during d-amphetamine maintenance relative to placebo maintenance. 
There were no significant effects on heart rate, diastolic pressure of body 
temperature. F-values and means are shown in Tables 3 and 4, respectively. 
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Figure 5. 
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Area-under-the-time-action curve (AUC). Analyses of area-under-the-time-
action curve data revealed a pattern of effects similar to those observed with 
analysis of peak effect data. F-values and means and for these analyses are 
shown in Tables 5 and 6, respectively. 
Cognitive Effects of d-Amphetamine and Placebo Maintenance 
Visual Probe Task. d-Amphetamine maintenance did not significantly affect of 
the measures on the Visual Probe Task. T-values and means and for these 
analyses are shown in Tables 9 and 10, respectively. 
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Table 9. T-values of cognitive tasks during maintenance days (Bold indicates a 
significant t-value). 
Outcome Measure  
T-Value 
Visual Probe Task  
Reaction Time Cocaine 1.0 
Reaction Time Neutral 0.5 
Attention Bias Score 1.0 
  
  Cocaine Stroop  
Reaction Time Cocaine 0.0 
Reaction Time Neutral 2.1 
Attention Bias Score 1.2 
  
Cued Go/No-Go Task  
Reaction Time  
Go Cue 1.2 
No Go Cue 3.6 
Inhibitory Failures  
Go Cue 0.0 
No Go Cue 1.1 
  
Balloon Analog Risk Task  
Percent Exploded 0.5 
  
Digit Symbol Substitution Task  
Trials Completed 0.0 
Trails Correct 0.9 
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Table 10. Means of cognitive tasks during maintenance days (Means [SEM]). 
Outcome Measure d-AMPH  
(0 mg) AM 
d-AMPH  
(0 mg) PM 
d-AMPH  
(40 mg) AM 
d-AMPH  
(40 mg) PM 
Visual Probe Task     
Reaction Time Cocaine 396.9 (23.9) 385.1 (22.6) 382.9 (26.7) 380.0 (33.5) 
Reaction Time Neutral 401.4 (26.0) 385.2 (22.2) 390.9 (27.9) 386.6 (29.2) 
Attention Bias Score 4.5 (7.2) 0.1 (4.1) 8.0 (6.2) 6.5 (6.4) 
     
Cocaine Stroop     
Reaction Time Cocaine 761.9 (41.4) 751.2 (39.6) 751.8 (43.7) 760.7 (43.0) 
Reaction Time Neutral 770.3 (40.8) 745.6 (39.6) 733.4 (37.6) 732.2 (38.2) 
Attention Bias Score -8.4 (17.8) 5.6 (7.5) 18.4 (19.1) 28.5 (12.6) 
     
Cued Go/No-Go Task     
Reaction Time     
Go Cue 295.5 (11.8) 285.2 (9.3) 287.6 (9.8) 282.3 (8.2) 
No Go Cue 324.2 (12.6) 324.7 (12.4) 304.8 (13.0) 308.6 (13.4) 
Inhibitory Failures     
Go Cue 0.1 (0.0) 0.2 (0.1) 0.1 (0.0) 0.2 (0.0) 
No Go Cue 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 
     
Balloon Analog Risk 
Task 
    
Percent Exploded 0.3 (0.1) 0.3 (0.0) 0.2 (0.0) 0.3 (0.0) 
     
Digit Symbol 
Substitution Task 
    
Trials Completed 44.8 (3.2) 46.9 (3.2) 45.2 (3.7) 46.4 (3.7) 
Trails Correct 42.0 (3.2) 43.5 (2.8) 40.2 (4.1) 40.4 (6.3) 
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Cocaine Stroop Task. d-Amphetamine maintenance did not significantly affect 
any of the measures on the Cocaine Stroop Task. T-values and means and for 
these analyses are shown in Tables 9 and 10, respectively. 
Cued Go/No Go Task. d-Amphetamine maintenance did not significantly 
affect inhibitory failures to a no-go target following a no-go cue on the Cued 
Go/No-Go task nor did d-amphetamine significantly affect inhibitory failures to a 
no-go target following a go cue on the Cued Go/No-Go task. d-Amphetamine 
maintenance decreased reaction time to a go target following a no-go cue. d-
Amphetamine maintenance did not affect reaction time to a go target following a 
go cue. T-values and means and for these analyses are shown in Tables 9 and 
10, respectively. 
Balloon Analog Risk Task (BART). d-Amphetamine maintenance did not 
significantly affect the percent of balloons exploded. T-values and means and for 
these analyses are shown in Tables 9 and 10, respectively. 
Digit-Symbol-Substitution Task (DSST). d-Amphetamine maintenance did not 
significantly affect the number of trials completed and trials correct. T-values and 
means and for these analyses are shown in Tables 11 and 12, respectively. 
Grooved Pegboard Task. d-Amphetamine maintenance did not significantly 
affect performance on the Grooved Pegboard Task. F-values and means and for 
these analyses are shown in Tables 11 and 12, respectively.
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Table 11. F-values for grooved pegboard during maintenance days (Bold indicates a significant F-value). 
Outcome 
Measure 
d-AMPH Time Replication d-AMPH x 
Time 
d-AMPH x 
Replication 
Time x 
Replication 
d-AMPH x Time 
x Replication 
Grooved 
Pegboard 
4.2 11.1 12.5 0.3 2.7 0.8 0.4 
65 
Table 12. Means of grooved pegboard during maintenance days (Means [SEM]). 
 d-AMPH (0 mg) 
Maintenance 
d-AMPH (40 mg) 
Maintenance 
Trial Number AM PM AM PM 
One 91.4 (2.8) 86.7 (2.7) 93.5 (2.9) 92.1 (2.6) 
Two 86.8 (2.0) 84.9 (2.3) 87.3 (3.0) 85.4 (2.2) 
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N-Back Task. d-Amphetamine maintenance did not significantly affect 
performance on the N-Back Task. F-values and means and for these analyses 
are shown in Tables 13 and 14, respectively.
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Table 13. F-values for N-Back Task during maintenance days (Bold indicates a significant F-value).  
Outcome Measure Number 
Back 
d-AMPH Time Back x  
d-AMPH 
Back x 
Time 
d-AMPH x 
Time 
Back x  
d-AMPH x 
Time 
N-Back        
Accuracy        
Target 3.0 2.1 0.3 0.3 3.1 0.0 0.1 
Non-Target 0.4 0.5 0.5 0.5 0.5 0.5 0.1 
Reaction Time        
Target 1.64 1.59 0.03 2.22 2.09 5.20 4.56 
Non-Target 3.1 0.0 0.1 0.2 0.0 2.1 2.2 
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Table 14. Means of N-Back Task during maintenance days (Means [SEM]). 
 
 d-AMPH (0 mg) d-AMPH (40 mg) 
N-Back AM PM AM PM 
One Back     
Accuracy     
Target 1.0 (0.0) 0.9 (0.1) 0.8 (0.1) 0.7 (0.1) 
Non-Target 0.8 (0.1) 0.9 (0.0) 0.8 (0.1) 0.8 (0.1) 
Reaction Time     
Target 643.8 (63.8) 637.0 (58.5) 646.1 (68.6) 669.7 (71.9) 
Non-Target 569.8 (98.2) 563.4 (70.2) 589.0 (77.2) 575.9 (73.0) 
     
Two Back     
Accuracy     
Target 0.8 (0.1) 0.9 (0.0) 0.7 (0.1) 0.8 (0.1) 
Non-Target 0.9 (0.0) 0.9 (0.1) 0.8 (0.1) 0.8 (0.1) 
Reaction Time     
Target 838.6 (113.0) 762.0 (96.9) 653.1 (99.0) 777.7 (117.7) 
Non-Target 768.4 (143.7) 661.8 (65.3) 683.2 (106.0) 750.7 (105.8) 
     
Three Back     
Accuracy     
Target 0.7 (0.1) 0.8 (0.1) 0.6 (0.1) 0.7 (0.1) 
Non-Target 0.9 (0.0) 0.9 (0.1) 0.8 (0.1) 0.8 (0.1) 
Reaction Time     
Target 847.9 (146.3) 688.4 (95.6) 718.9 (138.8) 787.6 (130.7) 
Non-Target 787.1 (116.9) 666.0 (70.4) 662.7 (104.7) 761.6 (113.3) 
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Chapter Six. Discussion 
Overall, methamphetamine acted as a reinforcer and was self-administered 
significantly more than placebo regardless of maintenance condition. d-
Amphetamine maintenance attenuated some of the subject-rated drug-effects of 
methamphetamine. There were generally no significant differences after placebo 
or methamphetamine administration on the cognitive battery during placebo and 
d-amphetamine maintenance. Methamphetamine was safe and well-tolerated 
during both placebo and d-amphetamine maintenance. Below is a discussion of 
these findings as they pertain to the current literature. 
Behavioral 
Intranasal methamphetamine was self-administered by participants more than 
placebo. This was shown across the range of doses with participants earning 
between eight and nine of the ten possible drug choices. This is consistent with 
previous research that has shown that intranasal methamphetamine functions as 
a robust reinforcer (Kirkpatrick, et al., 2011). Intranasal dosing was selected as 
the route of administration as it produces robust reinforcing effects.  
However, d-amphetamine maintenance did not significantly reduce self-
administration of methamphetamine. This result is similar to the results of two 
recent clinical trials that showed d-amphetamine treatment did not reduce 
methamphetamine use significantly compared to placebo (Galloway, et al., 2011, 
Longo, et al., 2009). However, these findings are inconsistent with results of 
another clinical trial that showed that d-amphetamine pretreatment reduced illicit 
use of amphetamine (Moeller, Schmitz, Herin, & Kjome, 2008). Similar to this 
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clinical trial, the data from the present study shows a clear trend of a downward 
shift in self-administration during d-amphetamine maintenance, however this 
decrease was not statistically significant. This suggests that it may be that a 
higher dose would be necessary to show a significant decrease in self-
administration. However, the higher doses, up to 110 mg/day have been tested in 
previous studies and did not significantly reduced methamphetamine self-
administration compared to placebo (Galloway, et al., 2011, Longo, et al., 2009), 
which suggests that the lack of a reduction of self-administration of 
methamphetamine during d-amphetamine maintenance may not be solely due to 
the dose tested. Overall, the concordance between the self-administration data 
and results of clinical trials shows that self-administration has predictive validity 
for outcomes that have been observed in clinical trials.  
Methamphetamine administered alone dose dependently increased positive 
subject-rated drug-effects (e.g., Like Drug; Willing to Take Again). This is 
consistent with previous literature that shows methamphetamine increases  
ratings of positive subject-rated drug-effects (Hart, et al., 2008; Hart, et al., 2011; 
Lile, Stoops, Glaser, Hays, & Rush, 2011; Perez, et al., 2008; Rush, Stoops, Lile, 
Glaser, & Hays, 2011; Rush, Stoops, Lile, Glaser, & Hays, 2011; Sevak, et al., 
2011; Stoops, 2006). d-Amphetamine maintenance attenuated some of the 
positive subject-rated drug-effects. The reduction of subject-rated drug-effects of 
methamphetamine during d-amphetamine maintenance is consistent with a 
previous study that showed 45 mg/day d-amphetamine reduced the subject-rated 
drug-effects of methamphetamine (Rush, Stoops, Lile, Glaser, & Hays, 2011). 
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The positive results of d-amphetamine to reduce subject-rated drug-effects of 
methamphetamine suggest that subject-rated drug-effects have poor predictive 
validity to model results observed in the clinic, producing false positives. Other 
medications have reduced the subject-rated drug-effects of stimulants, but were 
not effective clinically. Representative medications that have decreased subject-
rated drug-effects, but failed to decrease drug use in the clinic include 
risperidone (Grabowski, et al., 2000; Meredith, et al., 2009; Wachtel, Ortengren, 
& de Wit, 2002) and aripiprazole (Sevak, et al., 2011; Stoops, 2006; Tiihonen, et 
al., 2007). 
While the data from the current study combined with the findings of recent 
clinical trials (Galloway, et al., 2011, Longo, et al., 2009) suggest that d-
amphetamine may not be a viable pharmacotherapy for methamphetamine 
dependence, translational literature from studies testing agonist replacement for 
the treatment of cocaine suggest that a different agonist medication may be 
found that is an effective treatment (reviewed in: Herin, Rush, & Grabowski, 
2010; Moeller, Schmitz, Herin, & Kjome, 2008). Preclinical studies with rats and 
rhesus monkeys have shown that maintenance with d-amphetamine decreases 
cocaine self-administration (Chiodo, Läck, Roberts, 2008; Chiodo & Roberts, 
2009; Czoty, Gould, Martelle, & Nader, 2011; Czoty, Martelle, & Nader, 2010; 
Foltin & Evans, 1998; Negus & Mello, 2003a; Negus & Mello, 2003b; Peltier, Li, 
Lytle, Taylor, & Emmett-Oglesby, 1996). Human laboratory studies with healthy 
non-treatment seeking cocaine users have shown that maintenance on d-
amphetamine reduced some of the positive subjective effects of intranasal 
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cocaine and decreased self-administration of 20 mg of cocaine (Rush, Stoops, & 
Hays, 2009; Rush, Stoops, Sevak, & Hays, 2010). Finally, clinical trials have 
shown positive results using d-amphetamine as a potential treatment for cocaine 
dependence (Grabowski, et al., 2001; Grabowski, et al., 2004; Shearer, Wodak, 
van Beek, Mattick, & Lewis, 2003). 
Cognitive 
Effects of d-Amphetamine and Placebo Maintenance. Generally there were 
not significant differences in performance on the cognitive battery between d-
amphetamine and placebo maintenance. The only difference observed was that 
during d-amphetamine maintenance participants were quicker to respond to a go 
target following a no-go cue on the cued go/no-go task. As d-amphetamine is 
used to treat psychiatric disorders with deficits that have been proposed to be 
found in chronic stimulant abusers, the lack of difference in performance between 
maintenance conditions suggests that there may not be deficits present. 
Effects of Methamphetamine during d-amphetamine maintenance. Generally 
there were not differences in performance observed after methamphetamine 
administered either alone or in combination with d-amphetamine. The only 
significant difference observed was that participants had increased inhibitory 
failures to a no-go target following a no-go cue on the cued go/no-go task. This 
difference was attributed to a dose dependent decrease in performance when 
methamphetamine was administered during d-amphetamine maintenance only. 
This increase in inhibitory failures may be attributed to participants having 
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received two stimulant medications and the behavioral effects of a general 
increase activity. 
It is possible that the participants did not have significant deficits in cognitive 
functioning, as suggested in a recent review (Hart, Marvin, Silver, & Smith, 
2012). This review compiled previous studies that investigated cognitive 
performance in methamphetamine users and compared the results found to 
normative data for the assessments used when normative data was available. It 
was found that while deficits may be apparent when performance is compared to 
a control sample these deficits are not present when compared to age and 
education matched normative data (Hart, Marvin, Silver, & Smith, 2012). It would 
be expected that if impairments in cognitive functioning had existed, there should 
have been significant improvements observed after d-amphetamine was 
administered alone, but the only changes observed were a general reduction in 
time for participants to respond to go targets on the cued go/no-go task. 
Additionally, when methamphetamine and d-amphetamine were administered in 
combination there was a decrease in inhibitory control observed on the cued 
go/no-go task. The results of the present study combined with the recent review 
of cognitive performance in chronic stimulant users suggest that cognitive deficits 
may not be a viable target for treatment. 
Physiological 
Methamphetamine dose dependently increased systolic blood pressure 
during both d-amphetamine and placebo maintenance. However, these 
increases were attenuated during d-amphetamine maintenance. Additionally, 
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while the increases in systolic blood pressure were statistically significant, it was 
considered clinically insignificant and no participants were discharged from the 
study for medical reasons. There were no significant effects on heart rate, 
diastolic blood pressure, or temperature. Administration of methamphetamine 
during d-amphetamine maintenance produced an attenuated increase in systolic 
blood pressure, compared to administration of methamphetamine alone. This 
attenuation during d-amphetamine maintenance may be attributed to cross 
tolerance to the stimulating effects of methamphetamine. These findings are 
consistent with prior studies that have shown that intranasal methamphetamine 
administered is safe and well-tolerated (Hart, et al., 2008; Kirkpatrick, et al., 
2011; Lile, Stoops, Glaser, Hays, & Rush, 2011; Perez, et al. 2008; Rush, 
Stoops, Lile, Glaser, & Hays, 2011; Rush, Stoops, Lile, Glaser, & Hays, 2011; 
Sevak, Stoops, Hays, & Rush, 2009; Sevak, et al., 2011; Stoops, 2006). 
Future Directions 
 Future research should investigate the use of other agonist medications and 
combinations of medications for the treatment of methamphetamine dependence. 
It is possible that a dopamine transporter blocker would be best used for the 
treatment of methamphetamine abuse, as methamphetamine is a dopamine 
releaser. This is supported by past research that has shown that d-amphetamine, 
which is a dopamine releaser, has shown positive results for cocaine 
dependence, however methylphenidate, a dopamine transport blocker was 
ineffective. It is possible that methylphenidate may be an effective treatment for 
methamphetamine abuse, which is currently being assessed in a clinical trial. 
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Combinations of medications that are modestly effective alone, such as 
bupropion and naltrexone, should also be tested to see if the interaction of the 
medications is more effective than either medication alone. The combination of 
pharmacotherapy and behavioral therapy should also be assessed. Previous 
research has shown that the combination of levodopa and contingency 
management was more effective for cocaine dependence than levodopa or 
contingency management alone (Schmitz, et al., 2008). Additionally, future 
research is needed to investigate cognitive performance in chronic stimulant 
users to determine if it is a viable target for medications development. 
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